Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01441479 · ClinicalTrials.gov registry record

Strep A Fluorescent Immunoassay and Analyzer Field Study

A clinical trial of Strep Throat, sponsored by Quidel Corporation.

Completed
Registry status
1,282
Enrollment target
7
Study locations

NCT01441479 is a study of Strep Throat that has completed, run by Quidel Corporation. The registered enrollment target is 1,282 participants. The trial reports 7 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01441479, a study of Strep Throat, has completed, sponsored by Quidel Corporation.

COMPLETED
Registry status
1,282 participants
Enrollment target
7
Study locations

Study Summary

The purpose of this study is to demonstrate the ability of the Strep A Fluorescent Immunoassay Analyzer to accurately detect a throat swab specimen for the presence or absence of Strep A when compared to culture.

Conditions Studied

Interventions

  • DEVICE In Vitro Diagnostic Device aid in diagnosing

Study Locations (7)

California

  • La Costa Pediatrics - Carlsbad
  • La Jolla Pediatrics - San Diego

Arizona

  • Best Medical Group - Phoenix

Florida

  • Teena Hughes - Tampa

New Jersey

  • FastER Urgent Care - Morris Plains

New York

  • Twelve Corners Pediatrics - Rochester

Virginia

  • Advanced Pediatrics - Vienna

Trial Details

FieldValue
Enrollment Target 1,282 participants
Start Date 2011-06
Est. Completion 2012-12

Sponsor

Quidel Corporation

9 total trials

What the Registry Record Tells You About NCT01441479

The ClinicalTrials.gov registry entry for NCT01441479 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 1,282 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Quidel Corporation, which has 9 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Strep Throat appearing as the primary indexed condition, and to 1 intervention - of which In Vitro Diagnostic Device aid in diagnosing is the first listed.

NCT01441479 reports 7 study locations spanning 6 distinct geographic areas - top geographies include California, Arizona, Florida.

Frequently Asked Questions

What is clinical trial NCT01441479 about?

NCT01441479 is a clinical study titled "Strep A Fluorescent Immunoassay and Analyzer Field Study". The purpose of this study is to demonstrate the ability of the Strep A Fluorescent Immunoassay Analyzer to accurately detect a throat swab specimen for the presence or absence of Strep A when compared to culture.

What is the current status of trial NCT01441479?

This trial is currently completed. The enrollment target is 1,282 participants. The study started on 2011-06. Estimated completion is 2012-12.

What conditions does trial NCT01441479 study?

This clinical trial studies the following conditions: Strep Throat.

What interventions are being tested in trial NCT01441479?

The interventions under investigation include: In Vitro Diagnostic Device aid in diagnosing (DEVICE).

Who is sponsoring clinical trial NCT01441479?

This trial is sponsored by Quidel Corporation, which has 9 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01441479 being conducted?

This trial has 7 study locations across Arizona, California, Florida, New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Strep Throat

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.